NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $89.15 -0.94 (-1.05%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$89.16 +0.01 (+0.01%) As of 10/23/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$88.97▼$91.0550-Day Range$84.18▼$92.3652-Week Range$74.66▼$96.29Volume3.10 million shsAverage Volume3.56 million shsMarket Capitalization$51.33 billionP/E Ratio51.23Dividend YieldN/APrice Target$100.27Consensus RatingModerate Buy Company Overview Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders. Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures. Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally. Edwards Lifesciences operates through a global commercial and research network and is led by Chief Executive Officer Bernard Zovighian.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreEW MarketRank™: 3.683331105465 of 5 starsEdwards Lifesciences scored higher than 74% of companies evaluated by MarketBeat, and ranked 146th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 18 buy ratings, 7 hold ratings, and no sell ratings.Upside PotentialEdwards Lifesciences has a consensus price target of $100.27, representing about 12.5% upside from its current price of $89.15.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.00% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 13.00% in the coming year, from $3.00 to $3.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 51.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.57.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 51.23, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 194.94.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.36. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.66% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 4.96%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.58 News SentimentEdwards Lifesciences has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search InterestOnly 9 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows5 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $451,596.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesDoes Valve Repair Approval Change The Bull Case For Edwards Lifesciences (EW)?October 23 at 8:32 AM | finance.yahoo.comEdwards Lifesciences Gets Approval for Tricuspid Valve Repair System From US FDAOctober 21 at 8:07 PM | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's happening again this year. And next year. And the year after that. The people who understand this are already moving. In a free presentation I just recorded, I'm revealing what we call "The 2026 AI Gold Rush." The ONE AI-linked asset class the U.S. government has no choice but to fuel… and BlackRock, Goldman Sachs, and 170 public companies are already positioning into it. The same strategy that delivered 12,480% for Mastercard investors since its 2006 IPO. Sitting idle isn't "playing it safe." It's the most expensive decision you'll make this decade. | Decentralized Masters (Ad)Edward Wins FDA Approval For PASCAL System In Tricuspid Valve DiseaseOctober 21 at 2:59 PM | rttnews.comIntuitive Surgical's Q3 Earnings Beat Estimates on Strong System SalesOctober 21 at 9:58 AM | finance.yahoo.comFDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve DiseaseOctober 21 at 9:58 AM | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Stock Has Consensus Price Target of $100.27 According to BrokeragesOctober 21 at 2:28 AM | americanbankingnews.comEdwards Lifesciences (NYSE:EW) VP Sells $53,017.35 in StockOctober 9, 2026 | insidertrades.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW shares have increased by 4.6% and is now trading at $89.1480. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) announced its quarterly earnings results on Thursday, July, 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company's revenue for the quarter was up 13.6% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split before market open on Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' top institutional shareholders include Ninety One UK Ltd (2.07%), Assenagon Asset Management S.A. (0.47%), Birch Hill Investment Advisors LLC (0.13%) and Seilern Investment Management Ltd (0.10%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Donald E Bobo Jr, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Annette Bruls, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Salesforce (CRM), Adobe (ADBE), Visa (V), Mastercard (MA), Broadcom (AVGO) and Intuitive Surgical (ISRG). Company Calendar Last Earnings7/23/2026Today10/23/2026Investor update11/02/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$100.27 High Price Target$115.00 Low Price Target$85.00 Potential Upside/Downside+12.5%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage26 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio51.23 Forward P/E Ratio29.72 P/E Growth2.36Net Income$1.07 billion Net Margins15.43% Pretax Margin21.77% Return on Equity15.68% Return on Assets12.05% Debt Debt-to-Equity Ratio0.06 Current Ratio4.52 Quick Ratio3.77 Sales & Book Value Annual Sales$6.51 billion Price / Sales7.88 Cash Flow$2.82 per share Price / Cash Flow31.59 Book Value$17.81 per share Price / Book5.01Miscellaneous Outstanding Shares575,800,000Free Float574,015,000Market Cap$51.33 billion OptionableOptionable Beta0.87 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSE:EW) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
